AEON · AEON Biopharma, Inc.
$0.31
+0.02 (+5.31%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$12.55M
Shares
49.88M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Chad Oh | Chief Medical Officer | $1,381,767 |
| Alex Wilson | Chief Legal Officer | $1,365,333 |
| Robert Bancroft | President and Chief Executive Officer | $553,855 |
| Marc Forth | Former President and Chief Executive Officer | $135,616 |
| Jost Fischer | Former Interim President and Chief Executive Officer | — |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marc Forth | Former President and Chief Executive Officer | $5,044,599 |
| Chad Oh | Chief Medical Officer | $2,302,013 |
| Alex Wilson | Chief Legal Officer | $2,143,856 |
| Jost Fischer | Former Interim President and Chief Executive Officer | — |
| Robert Bancroft | President and Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Marc Forth | Former President and Chief Executive Officer | $3,982,378 |
| Chad Oh | Chief Medical Officer | $1,649,640 |
| Alex Wilson | Chief Legal Officer | $1,400,077 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Marc Forth | President and Chief Executive Officer | $4,804,637 |
| Chad Oh | Chief Medical Officer | $1,321,831 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Bencich | principal financial officer | Appointed | 2026-03-09 |
| John Bencich | Chief Financial Officer | Appointed | 2026-03-09 |
| Robert Bancroft | member of the Board to serve as a Class I director | Appointed | 2025-04-21 |
| Robert Bancroft | Principal Executive Officer, President, Chief Executive Officer | Appointed | 2025-04-21 |
| Jennifer Sy | Chief Accounting Officer and principal financial officer | Appointed | 2025-04-08 |
| Jost Fischer | Interim President, Chief Executive Officer and principal executive officer | Appointed | 2025-04-08 |
| Jost Fischer | Interim Chief Executive Officer | Appointed | 2025-03-27 |
| Marc Forth | President and Chief Executive Officer | Resigned | 2025-03-27 |
| Jennifer Sy | principal accounting officer | Appointed | 2024-05-16 |
| Peter Reynolds | Chief Financial Officer, principal financial officer and principal accounting officer | Terminated | 2024-05-16 |
| Seongsoo Park | Class III director | Appointed | 2024-04-17 |
| Robert Palmisano | Director (initial Class I director) | Appointed | 2023-07-27 |
| Shelley Thunen | Director (initial Class I director) | Appointed | 2023-07-27 |
| Eric Carter | Director (initial Class II director) | Appointed | 2023-07-27 |
| Jost Fischer | Director (initial Class II director) | Appointed | 2023-07-27 |
| Alex Wilson | Executive Vice President, Chief Legal Officer and Corporate Secretary | Appointed | 2023-07-27 |
| Marc Forth | Director (initial Class III director) | Appointed | 2023-07-27 |
| Jost Fischer | Chair of the Board | Appointed | 2023-07-27 |
| Peter Reynolds | Chief Financial Officer and principal financial officer and principal accounting officer | Appointed | 2023-07-27 |
| Chad Oh | Chief Medical Officer | Appointed | 2023-07-27 |
| Marc Forth | Chief Executive Officer and principal executive officer | Appointed | 2023-07-27 |
| Lance A. Berry | director | Appointed | 2021-02-12 |
| James Lightman | director | Appointed | 2021-02-12 |
| Julie B. Andrews | director | Appointed | 2021-02-12 |
Key facts
CIK
1837607
CUSIP
00791X209
13F (30d)
19 filings
19 filers
Visit website
Investor relations